FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124559501> ?p ?o ?g. }

• W3124559501 endingPage "712" @default.
• W3124559501 startingPage "704" @default.
• W3124559501 abstract "PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy. PATIENTS AND METHODS In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR). The secondary end points included safety, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS Among all 190 patients, the ORR was 20.5% with median DOR 12.8 months, median PFS 1.9 months, and median OS 17.4 months. Among 92 patients who failed at least two lines of systemic chemotherapy, the ORR was 23.9%. The ORRs were 27.1% and 19.4% in PD-L1+ and PD-L1− patients, respectively ( P = .31). Patients with ≥ 50% decrease of plasma Epstein-Barr virus (EBV) DNA copy number on day 28 had significantly better ORR than those with < 50% decrease, 48.3% versus 5.7% ( P = .0001). Tumor mutational burden had a median value of 0.95 muts/mega-base in the cohort and had no predictive value for response. Whole-exome sequencing results from 174 patients revealed that the patients with genomic amplification in 11q13 region or ETV6 genomic alterations had poor responses to toripalimab. CONCLUSION The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response." @default.
• W3124559501 created "2021-02-01" @default.
• W3124559501 creator A5001864411 @default.
• W3124559501 creator A5005126432 @default.
• W3124559501 creator A5006423482 @default.
• W3124559501 creator A5009866828 @default.
• W3124559501 creator A5020746135 @default.
• W3124559501 creator A5026060144 @default.
• W3124559501 creator A5030035495 @default.
• W3124559501 creator A5031452496 @default.
• W3124559501 creator A5043993720 @default.
• W3124559501 creator A5044825014 @default.
• W3124559501 creator A5049678335 @default.
• W3124559501 creator A5050027748 @default.
• W3124559501 creator A5051014138 @default.
• W3124559501 creator A5057769470 @default.
• W3124559501 creator A5059392900 @default.
• W3124559501 creator A5060591448 @default.
• W3124559501 creator A5062637798 @default.
• W3124559501 creator A5063300954 @default.
• W3124559501 creator A5069456938 @default.
• W3124559501 creator A5070745750 @default.
• W3124559501 creator A5071437727 @default.
• W3124559501 creator A5072823315 @default.
• W3124559501 creator A5076833306 @default.
• W3124559501 creator A5077722053 @default.
• W3124559501 date "2021-03-01" @default.
• W3124559501 modified "2023-10-16" @default.
• W3124559501 title "Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)" @default.
• W3124559501 cites W1505583194 @default.
• W3124559501 cites W2027671549 @default.
• W3124559501 cites W2031391029 @default.
• W3124559501 cites W2064811320 @default.
• W3124559501 cites W2096655221 @default.
• W3124559501 cites W2105955346 @default.
• W3124559501 cites W2111247797 @default.
• W3124559501 cites W2136147629 @default.
• W3124559501 cites W2218180658 @default.
• W3124559501 cites W2298696560 @default.
• W3124559501 cites W2509467148 @default.
• W3124559501 cites W2512237822 @default.
• W3124559501 cites W2522155417 @default.
• W3124559501 cites W2523194272 @default.
• W3124559501 cites W2529484692 @default.
• W3124559501 cites W2621593868 @default.
• W3124559501 cites W2747272999 @default.
• W3124559501 cites W2750488124 @default.
• W3124559501 cites W2755242535 @default.
• W3124559501 cites W2766816570 @default.
• W3124559501 cites W2794739281 @default.
• W3124559501 cites W2809159884 @default.
• W3124559501 cites W2810332541 @default.
• W3124559501 cites W2881137594 @default.
• W3124559501 cites W2890100090 @default.
• W3124559501 cites W2897422388 @default.
• W3124559501 cites W2909679049 @default.
• W3124559501 cites W2929216483 @default.
• W3124559501 cites W2943606118 @default.
• W3124559501 cites W2943721366 @default.
• W3124559501 cites W2945478948 @default.
• W3124559501 cites W2964560947 @default.
• W3124559501 cites W3005902575 @default.
• W3124559501 cites W3006656503 @default.
• W3124559501 cites W3012695695 @default.
• W3124559501 cites W3018980447 @default.
• W3124559501 cites W3038033452 @default.
• W3124559501 cites W3043438918 @default.
• W3124559501 cites W4211017340 @default.
• W3124559501 cites W4234835411 @default.
• W3124559501 doi "https://doi.org/10.1200/jco.20.02712" @default.
• W3124559501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8078488" @default.
• W3124559501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33492986" @default.
• W3124559501 hasPublicationYear "2021" @default.
• W3124559501 type Work @default.
• W3124559501 sameAs 3124559501 @default.
• W3124559501 citedByCount "124" @default.
• W3124559501 countsByYear W31245595012021 @default.
• W3124559501 countsByYear W31245595012022 @default.
• W3124559501 countsByYear W31245595012023 @default.
• W3124559501 crossrefType "journal-article" @default.
• W3124559501 hasAuthorship W3124559501A5001864411 @default.
• W3124559501 hasAuthorship W3124559501A5005126432 @default.
• W3124559501 hasAuthorship W3124559501A5006423482 @default.
• W3124559501 hasAuthorship W3124559501A5009866828 @default.
• W3124559501 hasAuthorship W3124559501A5020746135 @default.
• W3124559501 hasAuthorship W3124559501A5026060144 @default.
• W3124559501 hasAuthorship W3124559501A5030035495 @default.
• W3124559501 hasAuthorship W3124559501A5031452496 @default.
• W3124559501 hasAuthorship W3124559501A5043993720 @default.
• W3124559501 hasAuthorship W3124559501A5044825014 @default.
• W3124559501 hasAuthorship W3124559501A5049678335 @default.
• W3124559501 hasAuthorship W3124559501A5050027748 @default.
• W3124559501 hasAuthorship W3124559501A5051014138 @default.
• W3124559501 hasAuthorship W3124559501A5057769470 @default.
• W3124559501 hasAuthorship W3124559501A5059392900 @default.
• W3124559501 hasAuthorship W3124559501A5060591448 @default.
• W3124559501 hasAuthorship W3124559501A5062637798 @default.
• W3124559501 hasAuthorship W3124559501A5063300954 @default.

• next